Navigation Links
AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results
Date:3/11/2009

ses is mainly related to the continued results of cost-saving measures that were implemented beginning in the second quarter of 2008.

Consolidated research and development ("R&D") expenses were $12.3 million for the quarter ended December 31, 2008, compared to $13.6 million for the same quarter in 2007. The decrease in R&D expenses primarily relates to the comparative reduction in expenses incurred in connection with our Phase 3 program with cetrorelix in BPH, which by the fourth quarter of 2008 was fully enrolled and less subject to larger front-end expenditures that were necessary in the earlier, fourth quarter 2007 stage of the program.

Consolidated net loss was $14.5 million, or $0.27 per basic and diluted share for the quarter ended December 31, 2008, compared to $13.6 million, or $0.26 per basic and diluted share, for the same quarter in 2007. The increase in consolidated net loss is largely attributable to a combination of lower sales and royalties, lower license fee revenues, lower manufacturing margins on Cetrotide(R) due in part to a $0.7 million write-down to net realizable value of certain components of inventory, as well as to higher amortization expense, partly offset by lower quarter-over-quarter SG&A expenses, higher net foreign exchange gains and lower income tax expense.

Consolidated cash, cash equivalents and short-term investments were $49.7 million as at December 31, 2008.

CONSOLIDATED RESULTS FOR THE FULL YEAR ENDED DECEMBER 31, 2008

Consolidated revenues were $38.5 million for the year ended December 31, 2008, compared to $42.1 million for the year ended December 31, 2007. The decrease in consolidated revenues in 2008 compared to 2007 is primarily related to lower sales of Impavido(R), a decrease in consolidated license fee revenues mainly attributable to non-recurring milestone payments and the termination of a partner licensing agreement in 2007, partly offset by an increa
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014 -- A novel combination of microscopy and ... Energy,s Oak Ridge National Laboratory an unprecedented look at ... physical and electrochemical properties. , The research team ... the surface of a perovskite manganite, a complex material ... avenue to understand surface behavior could benefit researchers who ...
(Date:7/24/2014)... 24, 2014  Now available is a stem cell ... Regenerative Therapies , located in Guadalajara, Mexico ... people a new health option: stem cell therapies ... countless patients suffer from joint and muscle injuries due ... tears, torn rotator cuff, tennis elbow, and knee injuries. ...
(Date:7/24/2014)... Calif. , July 24, 2014  ECC West ... Denver, Colorado with University College Hospital (UCH) ... a development project to finance, design, construct, and operate ... Nigeria . Under the first of ... prepare scoping documents and funding applications. UCH Ibadan intends ...
(Date:7/24/2014)... A research team led by group leader Yung-Eun ... technology to synthesize sulfur-doped and nitrogen-doped graphenes which ... secondary batteries and fuel cells. Yung-Eun Sung is ... Nanoparticle Research at Institute for Basic Science* (IBS) ... , This achievement has great significance with regards ...
Breaking Biology Technology:ORNL study reveals new characteristics of complex oxide surfaces 2Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2
... present the 2011 "ALBERT EINSTEIN" World Award of Science ... Distinguished University Professor University of Toronto, Canada. ... Ozin as the winner of the 2011 "ALBERT EINSTEIN" ... the field of nanochemistry that have helped to define ...
... Pharmaceuticals, Inc. (Nasdaq: ANDS ) is updating the ... Nicolaus Healthcare Conference to Thursday, September 8, 2011 at 4:25 ... at the Four Seasons Hotel in Boston.  Steve Worland, Ph.D., ... overview of Anadys and its clinical development programs, setrobuvir and ...
... ALCLS), the French genome engineering specialist, will present at the UBS ... 2011, and at the MidCap Event in Paris on September 22 ... the activities and the development strategy of the Cellectis group at ... York hotel on Tuesday, September 20, 2011 at 11:30 am ET. ...
Cached Biology Technology:2011 Awards of World Cultural Council 22011 Awards of World Cultural Council 32011 Awards of World Cultural Council 42011 Awards of World Cultural Council 5Anadys Pharmaceuticals Updates Its Presentation Date at the Stifel Nicolaus Healthcare Conference 2
(Date:7/25/2014)... Canadian wildfires have been raging this summer and some of ... U.S. In this image collected by the Moderate Resolution ... 2014 a swath of smoke has descended over the Great ... interesting is the fire image from July 23, 2014 (first ... smoke as it drifts off southeastward. In the image, ...
(Date:7/25/2014)... Birla, associate professor of biomedical engineering at the ... on tissue engineering and artificial organ development., "Introduction ... comprehensive guide to entering into the field of ... professor of biomedical engineering at UH, served as ... that while there are other published books on ...
(Date:7/25/2014)... Spina bifda (SB) is a complex congenital central ... incomplete closing of the neural tubes during the ... spasticity, urinary and fecal incontinence and neurocognitive retardation. ... their quality of life. Researchers at Ankara Physical ... investigate the functional performance in children with SB, ...
Breaking Biology News(10 mins):University of Houston researcher publishes textbook on tissue engineering 2
... scientific studies of the effects on wildlife of large-scale ... assess their impact, especially in the desert Southwest, according ... Geological Survey and published in the journal BioScience ... the paper, USGS scientist Jeffrey Lovich and Maryville College ...
... oil spill in the Gulf of Mexico, the U.S. ... Engineering and National Research Council to convene a committee ... disaster and identify measures for preventing similar harm in ... IMPROVING OFFSHORE DRILLING SAFETY, the committee,s final report, analyzes ...
... believe decision making mechanisms in the human brain could mirror ... similarities have been found in decision making systems between humans ... bees could teach us about how our brains work. ... an often paralysing thought process in humans, with scouts who ...
Cached Biology News:Literature review on solar energy and wildlife impacts research 2Swarms of bees could unlock secrets to human brains 2
Can be used for the quantitative recovery of small amounts of nucleic acids within dilute solutions. 5mg/ml...
APOPTAG® Plastic Coverslips are designed to be custom fitted to the specific APOPTAG® kit application. Each coverslip has 2.5 x 1 dimensions....
Human VEGF-D Biotinylated MAb (Clone 78923)...
Recombinant Mouse TGF-beta RII/(human) Fc Chimera, CF...
Biology Products: